Application of urea in preparation of drugs resisting hyperuricemia and gout

A technology for hyperuricemia and urea, applied in the field of medicine, can solve problems such as no reports on the effect, and achieve the effects of treatment, prevention and treatment safety and reducing serum uric acid levels.

Inactive Publication Date: 2018-12-28
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In recent years, there have been reports on the antihypertensive and other pharmacological effects of allantoin, but its role in the preparation of anti-hyperuricemia and / or anti-gout drugs and / or health products has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of urea in preparation of drugs resisting hyperuricemia and gout
  • Application of urea in preparation of drugs resisting hyperuricemia and gout
  • Application of urea in preparation of drugs resisting hyperuricemia and gout

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0035] Experimental example 1. Allantoin reduces serum uric acid (UA) level in hyperuricemia model mice.

[0036]Experimental materials: Kunming mice were purchased from Beijing Huafukang Biotechnology Co., Ltd. Potassium oxonate, allantoin, allopurinol, benzbromarone were purchased from Sigma-Aldrich, Germany. Sodium carboxymethyl cellulose was purchased from Sinopharm Chemical Reagent Co., Ltd. The uric acid kit was purchased from Zhongsheng Beikong Biotechnology Co., Ltd.

[0037] Solution preparation: dissolve 1% sodium carboxymethyl cellulose, boil it, and use it as a solvent after cooling. Dissolve allantoin, potassium oxonate, allopurinol, and benzbromarone respectively to form a suspension.

[0038] Experimental grouping: 18-20g mice were randomly divided into normal control group, model group, benzbromarone group (25mg·kg -1 , positive control), allantoin low and high dose groups (100, 400mg·kg -1 ), 10 in each group.

[0039] Except for the control group, 300 mg...

experiment example 2

[0044] Experimental example 2. Effect of allantoin on the mRNA expression level of organic anion transporter 1 (OAT1) in hyperuricemia model mice. n=3.

[0045] Experimental grouping: 18-20g mice were randomly divided into normal control group, model group, benzbromarone group (25mg·kg -1 , positive control), allantoin low and high dose groups (100, 400mg·kg -1 ), 10 in each group. The relevant solution preparation and experimental scheme are the same as in Example 1. The reverse transcription kit and SYBR green dye were purchased from Biotech Co., Ltd. (TAKARA, Japan). Primers were purchased from Sangon Bioengineering Co., Ltd., and the purification method was HAP.

[0046] Table 2. OAT1 primers and internal reference primer sequences.

[0047]

[0048] After the mice were sacrificed, the kidneys of the mice were taken, and the total RNA in the kidneys was extracted by the Trizol method, and the RNA was quantified by a UV spectrophotometer, and then the corresponding...

experiment example 3

[0053] Experimental example 3. Effect of allantoin on the mRNA expression level of organic cation transporter 1 (OCTN1) in hyperuricemia model mice. ( n=3).

[0054] Experimental grouping: 18-20g mice were randomly divided into normal control group, model group, benzbromarone group (25mg·kg -1 , positive control), allantoin low and high dose groups (100, 400mg·kg -1 ), 10 in each group. The relevant solution preparation and experimental scheme are the same as in Example 2. The reverse transcription kit and SYBR green dye were purchased from Biotech Co., Ltd. (TAKARA, Japan). Primers were purchased from Sangon Bioengineering Co., Ltd., and the purification method was HAP.

[0055] Table 4. OCTN1 primers and internal reference primer sequences.

[0056]

[0057]

[0058] After the mice were sacrificed, the kidneys of the mice were taken, and the total RNA in the kidneys was extracted by the Trizol method, and the RNA was quantified by a UV spectrophotometer, and the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of urea in preparation of drugs resisting hyperuricemia and / gout and / or healthcare products. Hyperuricemia comprises primary and secondary hyperuricemia and the symptoms that the concentration of trioxypurine in blood is higher than 420 mmol / L (male) and 375 mmol / L (female) which are measured through a phosphotungstic acid reducing method, or the concentration of trioxypurine in the blood of adults is measured to be larger than 420 mmol / L through a uricase-peroxidase coupling method, and gout comprises primary gout and secondary gout. According to application, it is found that the serum uric acid level of mice can be remarkably reduced through allantoin, and mRNA expression of OAT1 and OCTN1 can be remarkably increased. Allantoin can be used for preparing the drugs resisting hyperuricemia and / gout and / or healthcare products, adverse reactions are reduced, and a safe, effective and economical solution is provided for treatment and prevention of diseases.

Description

technical field [0001] The present invention relates to a new application of allantoin in the preparation of medicines, mainly relates to the application of allantoin in the preparation of anti-gout drugs, in particular to the application of allantoin in the preparation of anti-hyperuricemia drugs and / or health care products, It belongs to the field of medical technology. Background technique [0002] Gout is a joint disease caused by crystal formation of monosodium urate deposition, which is directly related to hyperuricemia caused by purine metabolism disorder and / or decreased uric acid excretion. [0003] The latest point of view is that the clinical course of gout includes: (1) hyperuricemia, no uric acid crystals, no gout symptoms; (2) observed uric acid crystals or stones, no gout symptoms; (3) deposition of uric acid crystals in the body, acute gout Attack or history of attack; (4) Severe gout, with tophi formation, resulting in chronic gouty arthritis and gouty neph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4166A61P19/06
CPCA23L33/10A61K31/4166A23V2002/00
Inventor 杜冠华周启蒙杨海光王海港赵晓悦宋俊科方莲花
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap